Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Clozapine

An antipsychotic synthesised in Switzerland in 1958 and the founder of the atypical antipsychotics; approved in the United States in 1989, it is reserved for schizophrenia that does not respond to other treatments. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?At first many psychiatrists doubted it worked, because it did not cause stiffness and tremor: a true antipsychotic was believed to need them. This very difference is why it was called 'atypical'.

ClozapineGo to the active ingredient →
ClozapineActive ingredientClozapineCat. No. P-C231-001CAS 5786-21-0
Clozapine-d3Isotopically labelledClozapine-d3Cat. No. P-C231-013CAS 1215691-72-7
Clozapine-d4Isotopically labelledClozapine-d4Cat. No. P-C231-014CAS 204395-52-8
Clozapine-d8Isotopically labelledClozapine-d8Cat. No. P-C231-015CAS 1185053-50-2

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Reference substanceClozapine CRSEDQM code C2460000Family Clozapine

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.